Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

342

Participants

Timeline

Start Date

January 25, 2016

Primary Completion Date

October 19, 2018

Study Completion Date

October 19, 2018

Conditions

Small Cell Lung Cancer

Interventions

DRUG

Rovalpituzumab tesirine

Rovalpituzumab tesirine is a DLL3 targeted antibody drug conjugate (ADC).